ADPT Stock Analysis: Buy, Sell, or Hold?
ADPT - Adaptive Biotechnologies Corporation Common Stock
$13.22
0.09 (0.69%)
▲
5d:
-10.01%
30d:
-9.02%
90d:
-14.93%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 05, 2026
0d
Get Alerted When ADPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ADPT is down 10.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ADPT is down 10.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ADPT is currently trading at $13.22, which is considered oversold relative to its 30-day fair value range of $13.52 to $14.50.
Technical Outlook: Technically, ADPT is in a strong downtrend. The price is currently testing key support at $12.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.57 (+56.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADPT is in a strong downtrend. The price is currently testing key support at $12.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.57 (+56.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.52 -
$14.50
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 56.7% below Wall St target ($20.57)
- WARNING: Recommendation downgraded due to -10.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$13.52 -
$14.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$12.95
Resistance Level
$15.06
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-49.42
Wall Street Target
$20.57
(+56.7%)
Revenue Growth (YoY)
35.1%
Profit Margin
-16.8%
Share & Embed Analysis
Last updated: May 14, 2026 2:41 PM ET
Data refreshes hourly during market hours. Next update: 3:41 PM
Data refreshes hourly during market hours. Next update: 3:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Julie Rubinstein
SELL
19060 shares
2026-04-24
Julie Rubinstein
SELL
19060 shares
2026-04-22
Julie Rubinstein
SELL
30941 shares
2026-04-21
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$620 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$250 | 58 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$130 | 59 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 58 HOLD |
